Emerging Alzheimer's disease treatment paradigms: A late‐stage clinical trial review

Abstract INTRODUCTION Without disease‐modifying interventions, Medicare and Medicaid spending on Alzheimer's disease (AD) management is expected to reach 637 billion USD annually by 2050. The recent advent of promising AD therapies after decades of a near‐total failure rate in clinical trials sugges...

詳細記述

書誌詳細

主要な著者:	Jakub P. Hlávka, Andrew T. Kinoshita, Divya Jeyasingh, Cheng Huang, Leila Mirsafian, Mireille Jacobson
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2024-10-01
シリーズ:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
主題:	Alzheimer's disease clinical trials disease‐modifying therapy pharmaceutical pipeline pharmacoeconomics
オンライン･アクセス:	https://doi.org/10.1002/trc2.70022
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!